Who is sponsoring NCT00086333?

NCT00086333 is sponsored by Seagen Inc..

What condition does NCT00086333 study?

NCT00086333 studies Non-Small Cell Lung Carcinoma.

What drugs are being tested in NCT00086333?

Interventions: SGN-15, Docetaxel.

What is the status of NCT00086333?

NCT00086333 is currently COMPLETED.

Last reviewed 2011-10-21 · How we verify

A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent

NCT00086333 Phase 2 COMPLETED

This is an open-label, randomized phase II trial of a monoclonal antibody (mAb) drug immunoconjugate, SGN-15, administered weekly in combination with weekly docetaxel. The primary objective of the study is to determine the optimal interval between SGN-15 and docetaxel using FDG-PET imaging as a surrogate marker of response. In addition, clinical response rate, duration of response, and survival data will be collected.

Details

Lead sponsor	Seagen Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	30
Start date	2004-07
Completion	2005-12

Conditions

Non-Small Cell Lung Carcinoma

Interventions

SGN-15, Docetaxel

Countries

United States